Filing Flows › Collegium Pharmaceutical (COLL) › Q2 2025
Collegium Pharmaceutical (COLL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Collegium Pharmaceutical (COLL) reported revenue of $188M for the second quarter 2025 (Q2 2025), +29% from a year earlier and +6% from the quarter before. Operating margin was 18.7%, net earnings $12.0M (6.4% of revenue).
Collegium Pharmaceutical, Q2 2025: revenue $188M (+29% year over year), operating margin 18.7%, net earnings $12.0M, operating cash flow $72.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $188M | +6% | +29% |
| Gross profit | $108M | +11% | +19% |
| Operating profit | $35.1M | +62% | -26% |
| Net earnings | $12.0M | +396% | -39% |
| Operating cash flow | $72.4M | +31% | +7% |
| Free cash flow | $72.4M | +33% | +8% |
What changed
Revenue was $188.0M in Q2 2025, up 29% year over year and up 6% from the previous quarter. Xtampza ER was the largest line at 28% of revenue. Xtampza ER added $8.0M year over year (up 18%), 19% of the total change. Symproic declined 8%.
Gross margin was 57.7%, down 4.9 points from a year earlier. Operating profit was $35.1M, a 18.7% margin (down 14.0 points year over year). Operating profit fell $12.4M even though revenue rose $42.7M versus a year earlier, so costs grew faster than sales. Operating expenses grew 69% against revenue growth of 29%. Net earnings were $12.0M, down 39% year over year. The effective tax rate was 29.6%.
Operating cash flow was $72.4M (up 7% year over year), 605% of net earnings. Non-cash charges added back $56.6M of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items used $7.0M. Capital expenditures of $65K left free cash flow of $72.4M.
Questions
What was Collegium Pharmaceutical's revenue in the second quarter 2025?
Collegium Pharmaceutical (COLL) reported revenue of $188M for the second quarter 2025 (Q2 2025), +29% from a year earlier and +6% from the quarter before.
Was Collegium Pharmaceutical profitable in the second quarter 2025?
Operating profit was $35.1M (18.7% of revenue) and net earnings $12.0M.